• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在开发高效、选择性尿激酶2-萘甲脒抑制剂过程中新型结合相互作用的鉴定。N-苯基酰胺6-取代基的合成、结构分析及构效关系。

Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.

作者信息

Wendt Michael D, Rockway Todd W, Geyer Andrew, McClellan William, Weitzberg Moshe, Zhao Xumiao, Mantei Robert, Nienaber Vicki L, Stewart Kent, Klinghofer Vered, Giranda Vincent L

机构信息

Cancer Research and Structural Biology, Global Pharmaceutical R & D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-6101, USA.

出版信息

J Med Chem. 2004 Jan 15;47(2):303-24. doi: 10.1021/jm0300072.

DOI:10.1021/jm0300072
PMID:14711304
Abstract

The preparation and assessment of biological activity of 6-substituted 2-naphthamidine inhibitors of the serine protease urokinase plasminogen activator (uPA, or urokinase) is described. 2-Naphthamidine was chosen as a starting point based on synthetic considerations and on modeling of substituent vectors. Phenyl amides at the 6-position were found to improve binding; replacement of the amide with other two-atom linkers proved ineffective. The phenyl group itself is situated near the S1' subsite; substitutions off of the phenyl group accessed S1' and other distant binding regions. Three new points of interaction were defined and explored through ring substitution. A solvent-exposed salt bridge with the Asp60A carboxylate was formed using a 4-alkylamino group, improving affinity to K(i) = 40 nM. Inhibitors also accessed two hydrophobic regions. One interaction is characterized by a tight hydrophobic fit made with a small dimple largely defined by His57 and His99; a weaker, less specific interaction involves alkyl groups reaching into the broad prime-side protein binding region near Val41 and the Cys42-Cys58 disulfide, displacing water molecules and leading to small gains in activity. Many inhibitors accessed two of these three regions. Affinities range as low as K(i) = 6 nM, and many compounds had K(i) < 100 nM, while moderate to excellent selectivity was gained versus four of five members of a panel of relevant serine proteases. Also, some selectivity against trypsin was generated via the interaction with Asp60A. X-ray structures of many of these compounds were used to inform our inhibitor design and to increase our understanding of key interactions. In combination with our exploration of 8-substitution patterns, we have identified a number of novel binding interactions for uPA inhibitors.

摘要

本文描述了6-取代的2-萘甲脒类丝氨酸蛋白酶尿激酶型纤溶酶原激活剂(uPA,或尿激酶)抑制剂的制备及其生物活性评估。基于合成方面的考虑以及取代基向量的建模,选择2-萘甲脒作为起始点。发现6位的苯甲酰胺可改善结合;用其他双原子连接体取代酰胺证明无效。苯基本身位于S1'亚位点附近;苯基上的取代基可进入S1'和其他较远的结合区域。通过环取代定义并探索了三个新的相互作用点。使用4-烷基氨基形成了与Asp60A羧酸盐的溶剂暴露盐桥,将亲和力提高至K(i)=40 nM。抑制剂还可进入两个疏水区域。一种相互作用的特征是与一个主要由His57和His99定义的小凹陷形成紧密的疏水契合;一种较弱、特异性较低的相互作用涉及烷基伸入Val41和Cys42-Cys58二硫键附近的宽的prime侧蛋白质结合区域,取代水分子并导致活性略有提高。许多抑制剂可进入这三个区域中的两个。亲和力低至K(i)=6 nM,许多化合物的K(i)<100 nM,同时对一组相关丝氨酸蛋白酶的五个成员中的四个具有中度至优异的选择性。此外,通过与Asp60A的相互作用产生了对胰蛋白酶的一些选择性。许多这些化合物的X射线结构用于指导我们的抑制剂设计并增进我们对关键相互作用的理解。结合我们对8-取代模式的探索,我们已经确定了许多uPA抑制剂的新型结合相互作用。

相似文献

1
Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.在开发高效、选择性尿激酶2-萘甲脒抑制剂过程中新型结合相互作用的鉴定。N-苯基酰胺6-取代基的合成、结构分析及构效关系。
J Med Chem. 2004 Jan 15;47(2):303-24. doi: 10.1021/jm0300072.
2
In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.基于三肽的α-酮杂环作为凝血酶抑制剂的深入研究。S1'亚位点的有效利用及其对基于结构的药物设计的意义。
J Med Chem. 2005 Mar 24;48(6):1984-2008. doi: 10.1021/jm0303857.
3
Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors.与尿激酶S1β口袋的相互作用:8-杂环取代和6,8-二取代的2-萘甲脒尿激酶抑制剂
Bioorg Med Chem Lett. 2004 Jun 21;14(12):3063-8. doi: 10.1016/j.bmcl.2004.04.030.
4
Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).利用人工Ala190蛋白酶(Ala190 uPA)剖析和设计S1位点的抑制剂选择性决定因素。
J Mol Biol. 2004 Nov 19;344(2):527-47. doi: 10.1016/j.jmb.2004.09.032.
5
Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.基于三维定量构效关系比较分子场分析/比较分子相似性指数分析模型对尿激酶型纤溶酶原激活剂抑制剂结构要求的洞察。
J Med Chem. 2006 Jan 26;49(2):475-89. doi: 10.1021/jm050149r.
6
Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.明胶酶催化结构域的同源性建模及新型磺胺类抑制剂的对接模拟
J Med Chem. 1999 May 20;42(10):1723-38. doi: 10.1021/jm980514x.
7
Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).鉴定尿激酶型纤溶酶原激活剂(uPA)的口服生物可利用的非脒基抑制剂。
Bioorg Med Chem Lett. 2009 Oct 1;19(19):5712-5. doi: 10.1016/j.bmcl.2009.08.008. Epub 2009 Aug 7.
8
Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.利用类胰蛋白酶丝氨酸蛋白酶的S1亚位点实现选择性:尿激酶型纤溶酶原激活剂的强效和选择性抑制剂。
J Med Chem. 2001 Nov 8;44(23):3856-71. doi: 10.1021/jm010244+.
9
Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties.具有改善药代动力学性质的萘达米定尿激酶纤溶酶原激活剂抑制剂。
Bioorg Med Chem Lett. 2005 Jan 3;15(1):93-8. doi: 10.1016/j.bmcl.2004.10.026.
10
The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity.亮氨酸氨肽酶最有效的有机磷抑制剂。基于结构的设计、化学与活性。
J Med Chem. 2003 Jun 19;46(13):2641-55. doi: 10.1021/jm030795v.

引用本文的文献

1
A multilayer dynamic perturbation analysis method for predicting ligand-protein interactions.一种用于预测配体-蛋白质相互作用的多层动态扰动分析方法。
BMC Bioinformatics. 2022 Nov 2;23(1):456. doi: 10.1186/s12859-022-04995-2.
2
Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.尿激酶型纤溶酶原激活剂作为抗转移靶点:抑制剂设计原则、近期氨氯地平衍生物以及人/小鼠物种选择性问题
Biophys Rev. 2022 Jan 6;14(1):277-301. doi: 10.1007/s12551-021-00921-7. eCollection 2022 Feb.
3
Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens.
具有双脒结构的增强革兰氏阳性抗生素针对革兰氏阴性病原体的活性研究。
ACS Infect Dis. 2021 Dec 10;7(12):3314-3335. doi: 10.1021/acsinfecdis.1c00466. Epub 2021 Nov 12.
4
CHARMM-GUI for Template-Based Virtual Ligand Design in a Binding Site.CHARMM-GUI 用于结合部位基于模板的虚拟配体设计。
J Chem Inf Model. 2021 Nov 22;61(11):5336-5342. doi: 10.1021/acs.jcim.1c01156. Epub 2021 Nov 10.
5
Fragment-based drug discovery: opportunities for organic synthesis.基于片段的药物发现:有机合成的机遇
RSC Med Chem. 2020 Dec 24;12(3):321-329. doi: 10.1039/d0md00375a.
6
Structural analysis of experimental drugs binding to the SARS-CoV-2 target TMPRSS2.与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)靶点跨膜丝氨酸蛋白酶2(TMPRSS2)结合的实验性药物的结构分析
J Mol Graph Model. 2020 Nov;100:107710. doi: 10.1016/j.jmgm.2020.107710. Epub 2020 Aug 11.
7
Aryl and Arylalkyl Substituted 3-Hydroxypyridin-2(1H)-ones: Synthesis and Evaluation as Inhibitors of Influenza A Endonuclease.芳基和芳烷基取代的 3-羟基吡啶-2(1H)-酮:作为流感 A 内切酶抑制剂的合成与评价。
ChemMedChem. 2019 Jun 18;14(12):1204-1223. doi: 10.1002/cmdc.201900084. Epub 2019 May 14.
8
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.6-取代己二烯基氨甲酰基密胺衍生物作为人尿激酶型纤溶酶原激活物的高效和选择性抑制剂在癌症中的应用。
J Med Chem. 2018 Sep 27;61(18):8299-8320. doi: 10.1021/acs.jmedchem.8b00838. Epub 2018 Sep 7.
9
Lithium Hexamethyldisilazane Transformation of Transiently Protected 4-Aza/Benzimidazole Nitriles to Amidines and their Dimethyl Sulfoxide Mediated Imidazole Ring Formation.六甲基二硅氮烷锂将瞬态保护的 4-氮杂/苯并咪唑腈转化为脒及其二甲基亚砜介导的咪唑环形成。
Org Lett. 2016 Sep 16;18(18):4714-7. doi: 10.1021/acs.orglett.6b02359. Epub 2016 Sep 8.
10
New Frontiers in Druggability.药物可及性的新前沿
J Med Chem. 2015 Dec 10;58(23):9063-88. doi: 10.1021/acs.jmedchem.5b00586. Epub 2015 Aug 11.